Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
123
Views
29
CrossRef citations to date
0
Altmetric
Review

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

Ricardo Costa1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USACorrespondence[email protected]
,
Benedito A Carneiro1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Sunandana Chandra1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Sachin G Pai1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA
,
Young Kwang Chae1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Jason B Kaplan1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Hannah B Garrett1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA
,
Mark Agulnik1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Peter A Kopp3 Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
&
Francis J Giles1 Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, IL, USA;2 Division of Hematology and Oncology, Feinberg School of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
 show all
Pages 873-884 | Published online: 29 Feb 2016

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

He-Jiun Jiang, Yen-Hsiang Chang, Yen-Hao Chen, Che-Wei Wu, Pei-Wen Wang & Pi-Jung Hsiao. (2021) Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience. Cancer Management and Research 13, pages 7139-7148.
Read now

Articles from other publishers (28)

Jianxing Zhou, Zipeng Wei, You Zheng, Helin Xie, Wanxia Cao, Xinying Cai, Jialin Huang & Xuemei Wu. (2023) Disproportionality Analysis of Lenvatinib‐Caused Gastrointestinal Perforation in Cancer Patients: A Pharmacovigilance Analysis Based on the US Food and Drug Administration Adverse Event Reporting System. The Journal of Clinical Pharmacology 63:10, pages 1133-1140.
Crossref
L. J. Wirth, C. Durante, D. J. Topliss, E. Winquist, E. Robenshtok, H. Iwasaki, M. Luster, R. Elisei, S. Leboulleux & M. Tahara. (2023) Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Head and Neck Tumors (HNT) 12:4, pages 81-90.
Crossref
Marie Fabre, Lou Mateo, Diana Lamaa, Stéphanie Baillif, Gilles Pagès, Luc Demange, Cyril Ronco & Rachid Benhida. (2022) Recent Advances in Age-Related Macular Degeneration Therapies. Molecules 27:16, pages 5089.
Crossref
Lori J Wirth, Cosimo Durante, Duncan J Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux & Makoto Tahara. (2022) Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. The Oncologist 27:7, pages 565-572.
Crossref
Jieping Liu, Ling Huang, Mengqi Wan, Guilan Chen, Meile Su, Fang Han, Fasheng Liu, Guanghua Xiong, Xinjun Liao, Huiqiang Lu, Wanbo Li & Zigang Cao. (2022) Lenvatinib induces cardiac developmental toxicity in zebrafish embryos through regulation of Notch mediated‐oxidative stress generation. Environmental Toxicology 37:6, pages 1310-1320.
Crossref
Khalid Alshehri, Yousuf Alqurashi, Mazin Merdad, Shaza Samargandy, Razan Daghistani & Hani Marzouki. (2021) Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review. Cancer Reports 5:2.
Crossref
Viktoria F. Koehler & Jörg Bojunga. 2022. Therapie-Handbuch - Onkologie und Hämatologie. Therapie-Handbuch - Onkologie und Hämatologie 380 390 .
Chae Moon Hong, Ji Min Oh, Prakash Gangadaran, Ramya Lakshmi Rajendran & Byeong-Cheol Ahn. (2021) Treatment Effect of Combining Lenvatinib and Vemurafenib for BRAF Mutated Anaplastic Thyroid Cancer . International Journal of Thyroidology 14:2, pages 127-134.
Crossref
Daniel A. Hescheler, Burkhard Riemann, Milan J. M. Hartmann, Maximilian Michel, Michael Faust, Christiane J. Bruns, Hakan Alakus & Costanza Chiapponi. (2021) Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis. Frontiers in Endocrinology 12.
Crossref
Nada Bin Hareez, Mohammad Jay & Heather Lochnan. (2021) Papillary thyroid cancer with unusual late onset pituitary and orbital choroidal metastases. Case report and literature review. Journal of Clinical and Translational Endocrinology: Case Reports 20, pages 100081.
Crossref
Keisuke Enomoto, Shun Hirayama, Naoko Kumashiro, Xuefeng Jing, Takahito Kimura, Shunji Tamagawa, Ibu Matsuzaki, Shin-Ichi Murata & Muneki Hotomi. (2021) Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models. Cancers 13:4, pages 862.
Crossref
Mai-Huong Thi Ngo, Han-Yin Jeng, Yung-Che Kuo, Josephine Diony Nanda, Ageng Brahmadhi, Thai-Yen Ling, Te-Sheng Chang & Yen-Hua Huang. (2021) The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. International Journal of Molecular Sciences 22:4, pages 1931.
Crossref
Vera A. Kachko, Nadezhda M. Platonova, Vladimir E. Vanushko & Boris M. Shifman. (2020) The role of molecular testing in thyroid tumors. Problems of Endocrinology 66:3, pages 33-46.
Crossref
Ying Liang, Deyu Kong, Yi Zhang, Siqi Li, Yan Li, Anuradha Ramamoorthy & Junfeng Ma. (2020) Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells. Biotechnology and Bioprocess Engineering 25:2, pages 197-205.
Crossref
Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Juliet Hounsome, Rui Duarte & Aditya Shenoy. (2020) Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment 24:2, pages 1-180.
Crossref
Nai-Wei Sheu, He-Jiun Jiang, Che-Wei Wu, Feng-Yu Chiang, Hsin-Ying Clair Chiou & Pi-Jung Hsiao. (2019) Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. World Journal of Surgical Oncology 17:1.
Crossref
Elena Tirrò, Federica Martorana, Chiara Romano, Silvia Rita Vitale, Gianmarco Motta, Sandra Di Gregorio, Michele Massimino, Maria Stella Pennisi, Stefania Stella, Adriana Puma, Fiorenza Gianì, Marco Russo, Livia Manzella & Paolo Vigneri. (2019) Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes 10:9, pages 709.
Crossref
Silvia Martina Ferrari, Concettina La Motta, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Luca Quattrini, Sabrina Rosaria Paparo, Simona Piaggi, Armando Patrizio, Salvatore Ulisse, Enke Baldini, Gabriele Materazzi, Poupak Fallahi & Alessandro Antonelli. (2018) Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. Frontiers in Endocrinology 9.
Crossref
Masayuki Tori & Toshirou Shimo. (2018) Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. BMC Cancer 18:1.
Crossref
Seiichi Hayato, Robert Shumaker, Jim Ferry, Terri Binder, Corina E. Dutcus & Ziad Hussein. (2018) Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemotherapy and Pharmacology 82:6, pages 971-978.
Crossref
Jaume Capdevila, Kate Newbold, Lisa Licitra, Aron Popovtzer, Francesc Moreso, José Zamorano, Michael Kreissl, Javier Aller & Enrique Grande. (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews 69, pages 164-176.
Crossref
Yang Yu, Xiaohui Yu, Chenling Fan, Hong Wang, Renee Wang, Chen Feng & Haixia Guan. (2018) Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. Journal of Molecular Medicine 96:8, pages 777-790.
Crossref
Young Kwang Chae, Lauren Chiec, Scott K. Adney, Josh Waitzman, Ricardo Costa, Benedito Carneiro, Maria Matsangou, Mark Agulnik, Peter Kopp & Frank Giles. (2018) Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. Oncotarget 9:46, pages 28281-28289.
Crossref
Xian Wei, Ting Zhang, Yuqin Yao, Shaoxue Zeng, Min Li, Haotian Xiang, Chengjian Zhao, Guiqun Cao, Minhui Li, Ran Wan, Ping Yang & Jinliang Yang. (2018) Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Experimental Eye Research 168, pages 2-11.
Crossref
Monika Wagner, Hanane Khoury, Liga Bennetts, Patrizia Berto, Jenifer Ehreth, Xavier Badia & Mireille Goetghebeur. (2017) Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. BMC Cancer 17:1.
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
Roy Lirov, Francis P. Worden & Mark S. Cohen. (2017) The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies. Drugs 77:7, pages 733-745.
Crossref
Ole Ancker, Markus Wehland, Johann Bauer, Manfred Infanger & Daniela Grimm. (2017) The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors. International Journal of Molecular Sciences 18:3, pages 625.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.